ABPI response to MHRA guidance for the end of the transition period The MHRA has published information for pharmaceutical companies preparing for the end of the Brexit transition period. The guidance provides some information on how to operate from 1 January 2021, including on licensing of medicines and devices, clinical trials, exporting active substances for […]
Guidance on Brexit transition period
